secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001628280-22-021758
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics Q2 2022 net loss $14.6M; cash $152.4M; OV329 IND on track for H2 2022
--------------------------------------------------------------------------------

- Net loss $14.6M ($0.21 per share) vs $15.8M loss ($0.23) in Q2 2021.
- Cash, equivalents & marketable securities $152.4M, expected to fund pipeline into 2025.
- R&D expenses $6.0M (down from $7.7M) due to discontinuation of OV101 study and Takeda termination.
- OV329 IND submission and Phase 1 start planned for H2 2022; preclinical data shown at epilepsy meetings.
- KCC2 activator IND expected in 2024; Takeda reiterates soticlestat regulatory filing in FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828022021758/0001628280-22-021758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828022021758/ovid-20220809.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer